A5072718836- COVID-19 and healthcare impacts
- Lymphoma Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Neutropenia and Cancer Infections
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Long-Term Effects of COVID-19
- Cutaneous lymphoproliferative disorders research
- Protein Degradation and Inhibitors
- SARS-CoV-2 and COVID-19 Research
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Respiratory Support and Mechanisms
- Intensive Care Unit Cognitive Disorders
- COVID-19 Impact on Reproduction
- Salivary Gland Tumors Diagnosis and Treatment
- Healthcare Systems and Public Health
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Treatments and Mutations
- Viral-associated cancers and disorders
- Phagocytosis and Immune Regulation
- Autoimmune and Inflammatory Disorders
- Pharmacological Effects and Toxicity Studies
City Clinical Hospital
2020-2024
Sechenov University
2024
ORCID
2020
Moscow City Hospital No 29
2018
BACKGROUND. Renal failures, among them dialysis-dependent kidney disease, are common complications of multiple myeloma (ММ). Hemodialysis (HD) independence is achieved in only 20 % standard induction therapy recipients. The survival program HD patients remains unsatisfactory. Autologous hematopoietic stem cell transplantation (auto-HSCT) usually planned and performed young MM patients. However, the often excluded from high-dose chemotherapy protocols with subsequent auto-HSCT due to...
The term “Diffuse Large B-Cell Lymphoma” (DLBCL) covers an extremely heterogeneous range of aggressive hematological tumors lymphoid origin. recommended standard first-line treatment R-CHOP is still the leading therapy for newly diagnosed DLBCL. However, outcomes unified approach to chemotherapy disregarding a high clinical and molecular genetic heterogeneity this variant non-Hodgkin lymphoma are evaluated as unsatisfactory. This paper first in Russian Federation report personal experience...
Background . At the end of 2019, a new coronavirus infection caused by SARS-CoV-2 virus was registered. In March 2020, first cases COVID-19 were detected in Moscow. Patients with chronic lymphocytic leukemia, characterized profound immune dysfunction, have risk factors for severe viral disease. Aim To identify hospital mortality and course COVID-19, as well to optimize therapeutic preventive measures. Materials methods The analysis included 238 patients (142 (59 %) men 96 (41 women) leukemia...
Patients with acute leukemia are one of the most vulnerable risk groups for infection SARS-CoV-2 and severe course coronavirus infection. During first 2 years pandemic, mortality rate patients was 11-48 %, depending on type, only reached population levels in 2022. Risk factors COVID-19 old age, concomitant cardiac pathology, metabolic syndrome, absence remission. Chemotherapy administered month before hospitalization diagnosis showed statistical significance influencing hospital group...
Background . Acute myeloid leukemia (AML) is a highly aggressive oncological disease of the blood and bone marrow, requiring extremely toxic chemotherapy massive supportive treatment to achieve stable remission. Currently, there no work provide medical care these patients with high risk coronavirus infection. This paper presents results large AML patient cohort during COVID-19 pandemic. Aim To assess clinical features infection in patients. Materials methods A retrospective study included...
In December 2019, cases of severe respiratory infection were reported in Wuhan, China. The disease was caused by a new, previously undescribed coronavirus, structurally similar to the then known SARS-CoV virus. World Health Organization has named new virus SARS-CoV-2 and it causes COVID-19. problem COVID-19 is exacerbated rapid spread development life-threatening complications, main which pneumonia. Due severity condition, from 5 10 % patients are treated intensive care units. initially...
We describe a retrospective cohort, 156 patients with chronic lymphocytic leukemia (CLL) diagnosed COVID-19, analyze factors associated severe disease course and the effects of various treatment regimens. Anti-SARS-CoV-2 IgG IgM levels are significantly lower. Patients CLL more likely to have IL-6 acting as consistent biomarker severity. Ten had recurrent episodes, fatality rate 20%. Overall survival did not differ between receiving ibrutinib monotherapy anti-CD20 antibodies ± chemotherapy....
Aim . To study the course of COVID-19 (COronaVIrus Disease 2019) in elderly patients with acute myeloid leukemia (AML), to analyze risk factors for unfavorable outcome. Materials and methods The paper presents our own experience treatment (age ≥65 years) AML concomitant coronavirus infection hematology departments City Clinical Hospital No. 52 (Moscow) from March 2020 June 2022. diagnosis was considered confirmed based on a positive result polymerase chain reaction an oropharyngeal...
Background . Coronavirus disease (COVID-19), caused by SARS-CoV-2, presents new challenges to hematologists, highlighting the vulnerability of patients with hematological malignancies, in particular diffuse large B-cell lymphoma (DLBCL). Identification hospital mortality risk factors is necessary for subsequent stratification into groups, which will allow further risk-based therapy. Aim To develop a prognostic model and identify DLBCL associated COVID-19. Materials methods The interim...
Background . In March 2020, oncohematologists faced the problem of severe COVID-19 coronavirus infection in patients after a high-dose chemotherapy and autologous or allogeneic bone marrow transplantation. This required review issues related to selection for blood stem cell transplantation (HSCT), development new preventive therapeutic tactics aimed at treating infectious immunological complications this category, depending on nature status underlying disease timing treatment. Aim To assess...
Background . In March 2020, doctors faced the problem of severe COVID-19 coronavirus infection in patients with multiple myeloma. This required a review issues related to selection patients, development new preventive and therapeutic tactics aimed at treating infectious immunological complications this category, depending on nature status underlying disease timing treatment. Aim To assess severity myeloma, most common features course myeloma different therapy stages (disease onset,...
Background. The term diffuse large B-cell lymphoma (DLBCL) defines a heterogeneous group of lymphatic tumors. DLBCL is the most frequent immunomorphological variant among aggressive non-Hodgkin lymphomas (NHLs) in adults. It accounts for 30–40 % all NHLs. Long-term results treating newly diagnosed have not been reliably evidenced healthcare practice and, therefore, require further study.
 Aim. To assess efficacy chemotherapy terms 5-year progression-free survival (PFS) based on analysis...
Aim. To assess clinical efficacy and safety of the intensified program R-SD-EPOCH ± HDMTX (R-split-dose-EPOCH high-dose MTX) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
 Materials & Methods. From October 2022 to August 2023, 25 DLBCL were enrolled into trial protocol. Data 23 analyzed. The age was 46–70 years (median 63 years); there 13 women 10 men. Stage II bulky tumor lesion registered 7 patients; 16 showed advanced stages (III IV). IPI stratification...
Diffuse large B-cell lymphoma is the most common immunomorphological variant of in adults. Extranodal lesions are observed a third patients at disease onset. The organs often involved gastrointestinal tract, testicles, bones, thyroid gland, and skin. Primary involvement nasal cavity paranasal sinuses occur extremely rarely cause diagnostic therapeutic difficulties. article demonstrates rare clinical case newly diagnosed diffuse with sinonasal tract involvement. It took 6 months to verify...
Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment persistent COVID-19 in hematological malignancies. There is a need develop recommendations for management such patients, chemotherapy protocols, as well therapy case SARS-CoV-2 virus persistence. Doctors faced cases persistence, clinical manifestations during long course infectious process and not provided...
Aim. To evaluate the acute myeloid leukemia (AML) treatment efficacy in adults Moscow real clinical practice according to Cancer Registry data. Materials and methods. We retrospectively collected data from on permanent residents who were primary diagnosed with AML January 2019 November 2023. The effectiveness of antitumor therapy was assessed by complete remissions rate, relapses, deaths, 3-year overall relapse-free survival. Data analysis performed as 01.12.2023. Results. According...
Background. Patients with acute lymphoblastic leukemia (ALL) have been the most vulnerable group of patients at risk severe and extremely COVID-19 throughout coronavirus pandemic. Secondary immunodeficiency due to leukemia, as well antitumor treatment, predisposes development a more infection, long-term SARS-CoV-2 persistence even after complete regression symptoms. Thus, although emergence Omicron variant, infection began occur predominantly in mild form, ALL remains an urgent problem. Aim....
The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in December 2019 China and quickly spread throughout the world, causing a pandemic. most vulnerable to virus were patients with immunodeficiencies, cardiac pathology, diabetes mellitus. According international data, infection rate cancer is higher than general population [1]. presence of hematological diseases significantly aggravated course coronavirus SARS-CoV-2 (COVID-19). foreign more 80% required...
Background . Diffuse large B-cell lymphoma (DLBCL) is a potentially curable biologically heterogeneous lymphatic tumor. Standard R-CHOP therapy shows disappointing results, both immediate and longterm. To improve efficacy without additional toxicity, it worth considering the possibility of using oriented therapy. Aim evaluate clinical toxicity genotypedirected R-CHOP-X in patients with newly diagnosed DLBCL real practice. Materials methods A single-center prospective interventional study...
Classical Hodgkin’s lymphoma (cHL) is a lymphoproliferative disease characterized by the presence of Hodgkin anderezovsky–Reed–Sternberg cells and tumor microenvironment. Currently, much attention paid to microenvironment in cLH. A detailed understanding interaction between its opens up prospects for cHL diagnosis treatment. Innovative immunotherapeutic agents such as nivolumab make it possible control activate immune response. Despite high efficiency standard protocols young patients,...
In the era of COVID-19, chemotherapy patients with hematological malignancies has become cornerstone in hematology. Secondary immunodeficiency as a result hemoblastosis, predisposes to more severe course coronavirus infection, and specific antitumor treatment only exacerbates immunodeficiency. Thus, there is problem conducting during COVID-19 pandemic. At moment, are no unified recommendations for risk assessment choice oncohematological diseases concomitant infection. this article, we...
Topic: 30. Infections in hematology (incl. supportive care/therapy) Background: Despite the decline overall incidence of COVID-19 world, patients with acute lymphoblastic leukemia (ALL) remain a vulnerable group patients. Currently, coronavirus infection has predominantly mild course disease. However, positive polymerase chain reaction (PCR) test for SARS-CoV-2 may interfere treatment leukemia, delaying therapy and increasing risk ALL relapse. Aims: To identify independent variables...
Topic: 30. Infections in hematology (incl. supportive care/therapy) Background: Coronavirus infections (COVID-19) caused by SARS-CoV-2 present new challenges to hematologists, emphasizing the vulnerability of patients with hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL). Aims: Identification clinical and paraclinical predictors in-hospital case fatality DLBCL associated COVID-19. Methods: Between April 21, 2020, December 31, 2022, 103 (52 men, 51 women) remained...
Коронавирусная инфекция (COVID-19) – это острое респираторное заболевание, вызванное вирусом SARS-CoV-2, впервые было отмечено в городе Ухань (Китай) и быстро распространилось по всему миру. В условиях пандемии COVID-19 проведение специфического противоопухолевого лечения у пациентов с агрессивными В-клеточными лимфомами стало одной из сложных задач. Проведение специфической противоопухолевой терапии гемобластозами, том числе лимфопролиферативными заболеваниями, требует безотлагательного...